INTRODUCTION
HIV infection in women is primarily acquired across the cervicovaginal mucosa and there is a critical need for vaccines that induce immunity at this portal of entry. Early HIV infection can occur in intraepithelial CD4 T cells, and parallel Simian immunodeficiency virus models provide evidence that infection is spatially restricted to submucosal CD4 T cells for a few critical days before systemic dissemination ensues. [1] [2] [3] This brief period of localized infection in the cervicovaginal tissue represents a potential window of opportunity for rapid immune intervention by tissue-resident memory (T RM ) CD8 T cells if they can be generated in the genital tissues by vaccination.
T-cell subsets have conventionally been described as either central memory (T CM ) or effector memory (T EM ) based on their ability to continually migrate into secondary lymphoid organs or non-lymphoid tissues, respectively. 4 In contrast, T RM populations remain in non-lymphoid tissues long after the resolution of infection and exist in disequilibrium with migratory T-cell populations. [5] [6] [7] [8] [9] [10] [11] Unlike T EM and T CM cells, T RM cells are also commonly positioned at the frontline barrier of non-lymphoid tissues. 6, 12 T RM cells locally survey tissues for infected cells and initiate tissue-wide inflammation upon detection of cognate antigen, thus enhancing viral clearance. [13] [14] [15] [16] Recent studies have unequivocally demonstrated the critical functions of T RM cells in protecting mucosal tissues against infection by a range of viral pathogens including HSV, 17, 18 influenza, 19 and respiratory syncytial virus. 20 Large-scale T-cell vaccine efforts, including the STEP, Phambili, and HVTN505 trials in the recent decade have failed to demonstrate protective efficacy against sexually transmitted HIV. [21] [22] [23] [24] Despite observable systemic T-cell responses induced by these vaccine regimens and some evidence of a ''sieving'' effect on viral strains acquired by the vaccinees, 25, 26 it is likely that immediate clearance of infection in mucosal tissues would be inefficient given the temporal delay in anamnestic recall of systemic memory T-cell responses and dissemination of effector cells to the site of infection. 27, 28 Effective T-cell immunity against viruses at their entry points will likely require local seeding of mucosal tissue with CD8 T cells. In macaques vaccinated by attenuated CMV vectors, persistent induction and wide distribution of CD8 T EM cells in effector sites, including mucosal tissues, provided immunity against Simian immunodeficiency virus infection in B50% of vaccinated animals. 29, 30 In a subset of women highly exposed to HIV-1 that remained uninfected, HIV-specific CD8 T cells can be detected in the female reproductive tissues. 31 These studies allude to the importance of establishing CD8 T-cell immunity at the frontline niche of mucosal tissues to mount an effective and rapid response against genital HIV infection.
Here we demonstrate that HIV-specific CD8 T RM cells can be established in the vaginal mucosa of mice using mucosal vaccination strategies. Vaccination using recombinant influenza-HIV vectors resulted in the substantial shifting of HIVspecific CD8 T cells from the submucosa into the epithelium of the vaginal mucosa, thus priming the tissue against subsequent infection at the frontline barrier. Once established, we show that these cells can recognize vaginally administered HIV antigen and rapidly modulate inflammation in the vaginal mucosa. Antigen detection resulted in the upregulation of tissue addressin expression and the activation of a vaginal recruitment cascade for both adaptive and innate immune cells. The seeding of CD8 T RM cells into the vaginal mucosa, specifically in the epithelium compartment, may provide a rapid first line of defense against vaginal HIV infection.
RESULTS

Intravaginal boosting induces vaginal mucosal HIV-specific CD8 T cells
We recently developed recombinant influenza viruses expressing the HIV-1 Gag protein p24. 32 To induce CD8 T-cell immunity in the vaginal mucosa, a immunization regimen consisting of an intranasal prime followed by an intravaginal boost was performed. Intranasal immunization can prime cytotoxic T lymphocyte responses in the vaginal mucosa, which can be subsequently boosted by vaginal immunization. 33 The latter route of immunization results in more potent and sustained immunity in the vaginal mucosa. [34] [35] [36] Mice were sequentially immunized with an intranasal Flu(PR8)-p24 prime and an intravaginal Flu(X31)-p24 boost at doses of 10 5 and 10 7 p.f.u., respectively ( Figure 1a ). Before analyzing whole tissues by immunofluorescence microscopy, we conducted flow cytometric analyses to confirm that this immunization induced HIV-1 p24-specific CD8 T cells at this effector phase of 14 days after boost. Blood samples were analyzed for HIV-specific CD8 T-cell responses using a H2-K D tetramer loaded with the AI9 epitope of the p24 protein ( Figure 1b, top row) . Mock-immunized mice lacked HIVspecific CD8 T cells. In mice immunized with the Flu-p24 vectors, HIV-specific CD8 T-cell responses were readily detected in blood. We next analyzed mucosal samples to assess how this regimen effectively primed responses in the lung and vagina. HIV-specific CD8 T cells were readily detectable in lung bronchoalveolar lavage (BAL) samples 14 days after boost ( Figure 1b , middle row). Cell suspensions of vaginal tissues were analyzed at 14 days after boost, as per the gating strategy shown in Supplementary Figure S1A online. HIV-specific CD8 T-cell responses in the vaginal mucosa were comparable to responses observed in lung BAL samples (Figure 1b , bottom row). Mice immunized with influenza vector controls lacking HIV-1 p24 expression did not induce vaginal HIV-specific CD8 T-cell responses (Supplementary Figure S1B,C) . Overall, HIV-specific CD8 T-cell responses were significantly elevated in Flu-p24-immunized mice for all tissues investigated vs. mock-immunized mice (Figure 1d) , and are consistent with previous observations. 32 CD103 , a marker of tissue residency, was examined in all tissue compartments (Figure 1c ,e). CD103 expression was significantly increased in HIV-specific CD8 T cells of the vaginal mucosa compared with lung BAL samples, and was negligible in blood. These data demonstrated that an intranasal prime followed by an intravaginal boost immunization with the Flu-p24 vectors induced a high level of HIV-specific CD8 T RM cells in the vaginal mucosa and suggested that this immunization model would be suitable for detailed analyses by immunofluorescence microscopy.
In situ tetramer immunofluorescence microscopy as a method to increase detection of HIV-specific CD8 T cells in the vaginal mucosa Standard flow cytometry-based assays for non-lymphoid tissue analyses underestimate T RM cells by B70-fold compared with image-based quantitation. 37 Moreover, the anatomical localization of immune cells within non-lymphoid tissues is absent in flow cytometry-based assays of tissue suspensions. This information is relevant for T RM cells, which preferentially localize to the vaginal epithelium. 7, 12, 17, 35, 36 To address these limitations, we utilized in situ tetramer (IST) immunofluorescence staining to visually detect HIV-specific CD8 T cells in the vaginal mucosa and complement data generated by flow cytometry. 38 Whole fresh vaginal tissues were stained with the AI9 tetramer before cryopreservation and tissue sectioning, which differs from other published methods utilizing vibratome-based processing 39 or Qdot staining for equivalent detection of fluorescence. 40 Vaginal mucosal tissues from mice immunized with the Flup24 viruses were stained with H2-K D tetramers loaded with an HIV-1 p24 capsid AI9 peptide (AMQMLKETI) or an irrelevant TUM peptide (KYQAVTTTL). Tissues stained with the K D AI9 tetramer detected HIV-specific CD8 T cells only in immunized mice (Figure 2a,c) . The tetramer specificity for CD8 T cells was confirmed in tissues stained with the K D TUM tetramer, with no TUM-specific CD8 T cells detected (Figure 2b) . We observed some nonspecific tetramer staining (red cells, Figure 2c ), which is attributed to the interaction of excess phycoerythrin-conjugated streptavidin with fibronectin receptors of non-CD8 T cells. 41 Background tetramer staining was equivalent in non-CD8 cells stained with either the K D AI9 or K D TUM control tetramer (Supplementary Figure S2A) , confirming binding of excess phycoerythrin-conjugated streptavidin. Therefore, colocalized IST staining of tetramer and CD8 signals allowed accurate quantification and spatial enumeration of HIV-specific CD8 T cells in the vaginal mucosa.
Intravaginal immunization establishes effector HIV-specific CD8 T cells in the vaginal epithelium
We subsequently utilized the IST staining to quantify the immune response in the vaginal mucosa. The response was analyzed as a proportion of all nucleated cells, and the localization of HIV-specific CD8 T cells in either the lamina propria or epithelial compartment was also delineated. Responses in immunized mice were analyzed at the peak of the effector phase 14 days after the last vaccination (Figure 1a) .
At the effector phase, immunized mice displayed a significant increase in HIV-specific CD8 T cells in the vaginal mucosa at an average of 0.5 HIV-specific CD8 T cells per 1,000 nucleated cells (P ¼ 0.0001, Figure 3a) , confirming the IST staining results in Figure 2b . Conversely, HIV-specific CD8 T cells were not detected in mock-immunized mice. The HIVspecific CD8 T cells induced by immunization displayed significant spatial skewing toward the epithelial compartment of the vaginal mucosa as opposed to the lamina propria (P ¼ 0.001, Figure 3b ).
The total CD8 T-cell population was also analyzed, as this accounts for potential cytotoxic T lymphocytes specific for other HIV-or vector-associated epitopes not revealed by the tetramer analysis. Mock-immunized mice displayed a basal level of 1.7 CD8 T cells for every 1,000 nucleated cells of the vaginal mucosa. In contrast, immunized mice displayed a significantly elevated CD8 T-cell population, approaching 20 CD8 T cells per 1,000 nucleated cells (Po0.0001, Figure 3c ). The spatial localization of CD8 T cells was analyzed (Figure 3d) . Total CD8 T-cell localization of immunized mice displayed a significant bias (Po0.0001) towards the epithelium compartment, similar to that observed for the HIVspecific CD8 T cells. Conversely, mock-immunized mice showed more CD8 T cells in the lamina propria of the vaginal mucosa than in the epithelium (Po0.0001). The mucosal prime-boost immunization regimen, therefore, induced infiltration of both HIV-specific and total CD8 T-cells into the vaginal mucosa, which displayed a propensity to localize in the epithelium compartment.
Intravaginal immunization establishes memory HIV-specific CD8 T cells in the vaginal mucosa
Having established that HIV-specific CD8 T cells can be seeded into the vaginal epithelium, we next assessed the durability of this response. In studies investigating T RM lodgement in the skin or vaginal mucosa, CD8 T cells displayed T RM phenotypes and fixed epithelial compartmentalization by week 4 after infection and beyond. 6, 12, 17, 36 To investigate the HIV-specific CD8 T-cell memory response, immunized mice were analyzed 30 days after the last vaccination (Figure 4a) .
At this memory time point, most immunized mice retained vaginal HIV-specific CD8 T cells at an average of 0.26 cells for every 1,000 nucleated cells (Po0.0001, Figure 4b ). In contrast, HIV-specific CD8 T cells were not detected in mockimmunized mice. The distribution of memory HIV-specific CD8 T cells between the epithelium and lamina propria was similar ( Figure 4c) .
Total CD8 T cells remained significantly elevated in the vaginal mucosa 30 days after the last vaccination (Po0.0001, Figure 4d ), maintaining a sixfold increase compared with mock-immunized mice. Mirroring the response at 14 days after the last vaccination, total vaginal CD8 T cells of immunized mice displayed a significant bias (Po0.05) in spatial localization toward the epithelium compartment 30 days after the last immunization ( Figure 4e ). In contrast, mockimmunized mice maintained a significant preferential skewing (Po0.05) of CD8 T cells toward the lamina propria of the vaginal mucosa. Lamina propria CD8 T cells in mockimmunized mice at the memory phase were reduced compared with mock-immunized mice at the effector phase ( Figure 3d vs. Figure 4e ) because of potential waning of progesterone administered before immunization, which decreases vaginal CD8 T-cell infiltration as described previously. 42 Thus, both HIV-specific and total CD8 T cells were retained in the vaginal mucosa 4 weeks after boost, of which a proportion were spatially maintained in the epithelium.
Maintenance of HIV-specific CD8 T cells between the effector and memory phase
We investigated the level of waning in vaginal CD8 T cells and if there was a preferential retention of HIV-specific CD8 T cells over the total CD8 T cells in the vaginal mucosa. As immunizations for the peak effector (14 days after boost) and memory (30 days after boost) phase were initiated concurrently, HIV-specific and total CD8 T-cell responses of both phases could be directly compared. Total CD8 T cells decreased significantly by 4.2-fold as the effector phase progressed to the memory phase (Po0.001, Figure 5a ). Concurrently, absolute counts of HIV-specific CD8 T cells were reduced by 1.9-fold from the effector to memory phase progression, although this was not significant (P ¼ 0.24, Figure 5b ). HIV-specific CD8 T cells as a percentage of total CD8 T cells increased by 2.5-fold from effector to memory phase, but was not significant (P ¼ 0.30, Figure 5c ). Despite a significant decrease in total CD8 T cells within the vaginal mucosa, HIV-specific CD8 T cells did not display a similar extent of reduction in both absolute and percentage terms.
The tissue-residency marker, CD103, promotes CD8 T-cell retention in the vaginal mucosa and has been associated with improved control of viral infections. 17, 43 We compared CD103 expression levels in HIV-specific CD8 T-cells by flow Spatial distribution of total CD8 T cells in the vaginal mucosa. Graphs represent data combined from two experiments (n ¼ 9-11 mice per treatment group), bars represent median values, and P values were derived from Mann-Whitney statistical testing. i.n., intranasal; ND, not detected; PBS, phosphate-buffered saline.
cytometry at the peak effector and memory phase (Figure 5d ,e). High levels of CD103 expression were maintained with no significant reduction from the effector to memory phase. To complement the flow cytometry data, we investigated the colocalized expression of CD103 on HIVspecific CD8 T cells at the memory phase by confocal microscopy ( Figure 5f ). HIV-specific CD8 T cells present in the epithelial compartment displayed CD103 expression, and conversely, CD103 expression was absent for HIV-specific CD8 T cells localized in the lamina propria ( Figure 5g ). These observations suggest that HIV-specific CD8 T cells induced by immunization displayed tissue-resident properties early during the effector phase and were maintained later in the memory phase.
In vivo reactivation of vaginal-resident HIV-specific CD8 T cells induces infiltration of peripheral CD8 T cells
T RM cells function as frontline sensors in non-lymphoid tissues such as the vaginal mucosa and can initiate rapid recruitment of peripheral immune cells upon antigen-specific activation. 8, 14 As a model to assess the functional capacity of vaginal-resident memory HIV-specific CD8 T cells, we inoculated immunized animals intravaginally with either the HIV AI9 peptide (AMQMLKETI) or an irrelevant LYL peptide (LYLVCGERL), and tissue-wide activation was assessed 2 days later ( Figure 6a) . mice instilled with the LYL peptide (Po0.0001, Figure 6c ). The average for total CD8 T cells was lowest in mock-immunized mice. The increase in HIV-specific CD8 T cells in vaccinated mice receiving the AI9 peptide was not statistically significant, although median levels were elevated by 2.8-fold compared with mice receiving the LYL peptide (P ¼ 0.08, Figure 6d ). Vaccinated mice receiving the AI9 peptide displayed a significant correlation between HIVspecific CD8 T cells and total CD8 T cells (Po0.05, Figure 6e ), suggesting that the magnitude of total CD8 T-cell recruitment was regulated by the population size of HIV-specific CD8 T cells upon reactivation. HIV-specific CD8
Reactivation of HIV-specific CD8 T RM cells induced infiltration of CD8 T cells into the vagina (Figure 6b
T cells showed significant upregulation of CD44 hi CD62 lo phenotype upon AI9 instillation, which indicates recent T-cell activation [44] [45] [46] (Figure 6f,g ). Ki67 staining confirmed that the increase in total CD8 T-cell numbers was largely due to infiltration as opposed to in situ proliferation (Figure 6h,i) . In support of this, total CD8 T cells also showed an increase in CD62L (L-selectin) expression (Figure 6j,k) , which is indicative of activated CD8 T-cell recruitment from peripheral circulation into sites of inflammation. 47 Thus, we demonstrate here that recognition of cognate antigen by HIVspecific CD8 T RM cells resulted in the rapid recruitment of peripheral CD8 T cells. Antigen recognition by CD8 T RM cells can initiate expression of adhesion molecules in inflamed tissues, which results in downstream recruitment of peripheral effector cells. 8, 14 We analyzed vaginal tissues for the expression of vascular cell adhesion molecule-1 after reactivation of HIV-specific CD8 T RM cells.
14 Intravaginal administration of the AI9 peptide increased VCAM-1 expression on vaginal endothelial vessels (Figure 7a) . Conversely, mice administered with the non-relevant LYL peptide displayed low levels of VCAM-1 expression. The mean fluorescence intensity of VCAM-1 in vaccinated mice receiving the AI9 peptide was significantly increased by 1.9-fold in contrast to vaccinated mice receiving the non-relevant LYL peptide (P ¼ 0.0001, Figure 7b ). Mock-immunized mice receiving the AI9 peptide showed basal levels of VCAM-1 expression, indicating that reactivation of HIV-specific CD8 T RM cells was a prerequisite for increased VCAM-1 expression.
As activation of CD8 T RM cells may lead to recruitment of multiple effector cell types into tissues, we compared the number of B cells, natural killer (NK) cells, and CD4 T cells in Figure S3) . Conversely, mockimmunized mice and LYL-administered mice displayed low levels of B-cell infiltration. NK cell recruitment was analyzed by NKp46 staining, which was previously demonstrated to be reflective of NK cell populations in nonlymphoid tissues. 48, 49 Innate NK cells also increased significantly by 2.8-fold following reactivation of HIV-specific CD8 T RM cells in vaccinated mice with the AI9 peptide (Po0.0001, Figure 7e ,f). CD4 T cells were significantly elevated by 2.1-fold in vaccinated mice that received the AI9 peptide intravaginally compared with LYL-administered mice (Po0.01, Figure 7g,h) . As an influx in CD4 T cells may increase the risk of HIV-1 acquisition, we examined the potential recruitment of CD4 T cells that express the coreceptor C-C motif chemokine receptor 5 (CCR5), which is required for viral fusion by most transmitted HIV-1 strains (Figure 7i-k) . 50, 51 Although reactivation of HIV-specific CD8 T RM cells induced an increase in total CD4 T cells, the percentage of CD4 T cells expressing CCR5 did not significantly increase (Figure 7i,j) . However, the absolute cell count of CD4 T cells expressing CCR5 was significantly elevated as a result of AI9 peptide activation in vaccinated mice (Figure 7k ).
We also examined if whole inactivated virus (aldrithiol-2-treated HIV-1) could similarly reactivate HIV-specific CD8 T RM cells in the vaginal mucosa, which would require uptake of viral particles by antigen-presenting cells and subsequent crosspresentation to CD8 T RM cells (Supplementary Figure S4A) . 52 With the exception of a significant increase in total CD8 T cells (Po0.05) (Supplementary Figure S4D) , VCAM-1, total T-cells (i.e. CD3) and HIV-specific CD8 T-cells in vaccinated mice receiving whole inactivated virus were comparable to vaccinated mice instilled with a negative control microvesicle solution (Supplementary Figures  S4B,C,E) . In contrast to direct peptide instillation, the stimulation of HIV-specific CD8 T RM cells by whole inactivated viral particles did not induce the associated tissue-wide responses previously observed.
These studies highlight that reactivation of HIV-specific CD8 T RM cells in the vaginal mucosa can be achieved by direct recognition of cognate peptide. Furthermore, this effect was highly specific to the HIV antigen and was not observed with an irrelevant antigen. Cognate antigen recognition rapidly resulted in tissue-wide recruitment of both adaptive and innate immune cells that also coincided with increased expression of addressin molecules on endothelial vessels in the vaginal mucosa. viral infections has been illustrated in several important studies. 6, 7, 9, [17] [18] [19] [20] Using a prime-boost mucosal regimen involving heterologous recombinant influenza vectors expressing the HIV-1 p24 capsid protein, we demonstrate that a mucosal vaccination regimen combining intranasal and intravaginal routes induces vaginal-resident HIV-specific CD8 T cells. Furthermore, this mucosal vaccination strategy primed CD8 T cells to preferentially localize to the epithelial compartment of the vaginal mucosa. Established HIV-specific CD8 T RM cells could detect cognate HIV antigen intravaginally and trigger a robust anamnestic response within the vaginal mucosa. HIV-specific CD8 T RM cell reactivation resulted in increased addressin expression on vaginal endothelial vasculature. Moreover, vascular activation was coupled with heightened infiltration of both adaptive and innate immune cells.
In this study, vaginal CD8 T cells showed considerable difference in their spatial distribution pre-and postimmunization. Before immunization, the majority of CD8 T cells resided in the lamina propria, indicating that these populations were likely to be migratory. 12 Immunization led to a significant shift in the anatomical localization of CD8 T cells, with these cells skewed toward the epithelial compartment. This redistribution may have a crucial role in intercepting early HIV transmission and for the clearance of infected cells residing in the intraepithelial compartment. Direct infection of vaginal intraepithelial CD4 T cells expressing CCR5 occur in the earliest phases of productive HIV infection. 3 Resident dendritic cells expressing C-type lectin receptors can also bind HIV-1 by gp120 association. 53, 54 Similarly, epithelial Langerhan cells productively uptake HIV-1 and form infectious synapses with T cells. 3 Infected cells can migrate out of the vaginal epithelial compartment, leading to subsequent viral amplification in the lamina propria or draining lymph nodes before systemic dissemination. Previous large-scale T-cell vaccine trials (STEP and Phambili) have largely focused on inducing systemic immunity towards HIV, which failed to demonstrate protection against sexually transmitted HIV. [21] [22] [23] Although systemic responses induced by these vaccine regimens displayed observable magnitude and cytokine functionality, seeding of CD8 T cells into genital mucosal tissues was likely inadequate for the effective control of infection at its entry point. HIV vaccines that generate CD8 T RM cells within the epithelial compartment of the female reproductive tract could circumvent the temporal delay associated with anamnestic recall of peripheral memory CD8 T cells, and therefore provide the rapid cell-mediated functions required to halt the earliest phases of genital HIV infection.
We show that HIV-specific CD8 T cells displayed a tissueresident phenotype in the vaginal epithelium compartment 30 days after the last immunization. This was demonstrated by the expression of CD103, a marker of CD8 T-cell maintenance in the female reproductive tract of mice and humans. 43, 55 Despite high and stable expression of CD103 between day 14 and 30 postimmunization shown in our studies, a modest reduction in HIV-specific CD8 T cells was observed. The magnitude in decline from 14 to 30 days after immunization of HIV-specific CD8 T cells was, however, less compared with the reduction in total vaginal CD8 T cells. This observation is in agreement with a recent study showing that although trafficking of total CD8 T cells into non-lymphoid tissues was elevated and indiscriminate early in vaccinia infection, only antigen-specific CD8 T cells were preferentially retained after the resolution of infection. 56 Retention of HIV-specific CD8 T cells in the vaginal mucosa may mirror the kinetics of CD8 T RM cells in lungs, in which a steady rate of attrition was observed over time compared with stable populations in other non-lymphoid sites such as skin. 17, 19, 57 Despite a 1.9-fold decrease in vaginalresident HIV-specific CD8 T cells, the remaining cells displayed the capacity for in situ reactivation following HIV peptide delivery to the vagina. Although the presence of T RM cells at 30 days after infection has been shown to predict long-term residency and protection, 6, 12, 17, 18, 36 it will be important in future studies to address the degree to which even longer-term persistence of HIV-specific CD8 T cells can be generated by our vaccination model.
We expected that the reactivation of vaginal CD8 T RM cells would have induced rapid proliferation and peripheral recruitment of other HIV-specific CD8 T cells. An overall 2.8-fold increase in absolute numbers of HIV-specific CD8 T cells was observed; however, this was variable across the mice studied and did not reach significance. Other studies have shown that the reactivation of CD8 T RM cells induces significant accumulation of antigen-specific CD8 T cells in a similar 2-day period. 8, 14 The number of HIV-specific CD8 T RM cells before reactivation measured in our study was comparatively lower than the CD8 T RM cell densities observed in these previous studies. This difference in CD8 T RM cell quantities established within the tissue before antigen reactivation may likely influence the downstream influx rate of other immune cells, with higher densities resulting in more rapid recruitment. Future studies could more finely optimize the density of HIVspecific CD8 T RM cells within the vaginal mucosa and analyze the corresponding time course of recruitment of both HIVspecific CD8 T RM cells and other immune cell populations after antigen exposure in the vagina.
Upon CD8 T RM cell reactivation, increased infiltration of CD4 T cells was observed. We performed the peptide inoculation as a surrogate of viral reinfection, and under circumstances of an actual infection, the elevation in target CD4 T cells could inadvertently result in a more rapid dissemination of HIV within the vaginal mucosa. Our studies specifically demonstrate that absolute numbers of CCR5-expressing CD4 T cells were elevated in the vaginal mucosa postpeptide instillation, suggesting a potential increased risk of infection early after CD8 T RM reactivation. Conversely, while an influx of activated CD4 T cells present more potential target cells, CD4 T cells may also serve to enhance viral clearance and promote cytotoxic T lymphocyte responses. 9, 58, 59 In individuals acutely infected with HIV, HIV-specific CD4 T cells displaying cytolytic properties contribute to the control of viral replication. 60 Although robust anti-viral responses can be achieved with CD8 ARTICLES MucosalImmunology | VOLUME 11 NUMBER 3 | MAY 2018
T RM cell reactivation, our data suggest that caution should be taken with the use of T RM -based vaccine strategies against HIV. These risks and benefits of an expanded CD4 T-cell population driven by CD8 T RM cell reactivation or the ability to selectively induce reactivation without the recruitment of HIV target cells will require further investigation.
B-cell infiltration was similarly enhanced in the vaginal mucosa, which suggests that humoral-mediated responses could also be promoted by the activation of CD8 T RM cells. We also found that B-cell infiltration was significantly correlated to the number of HIV-specific CD8 T RM cells post-AI9 reactivation. Several studies have demonstrated strong association of anti-HIV activity in females with high levels of cervicovaginal immunoglobulin G or A. [61] [62] [63] If combined with a humoral vaccination regimen, CD8 T RM cells could conceivably recruit B cells expressing HIV-specific antibodies rapidly to the vaginal mucosa after viral exposure. The observed elevation of innate NK cell numbers following CD8 T RM cell reactivation could also potentiate anti-viral defenses, whereby the distinct cytolytic capabilities of NK cells and CD8 T cells are harnessed simultaneously for the clearance of mucosal HIV infection. NK cell-mediated immunity by antibody-dependent cellular cytotoxicity likely conferred modest levels of protection in the RV144 HIV vaccine efficacy trial. [64] [65] [66] Vaccine regimens that induce non-neutralizing antibody-dependent cellular cytotoxicity antibodies and concurrent seeding of mucosal CD8 T RM cells could be utilized as a strategy for rapid viral clearance in the vaginal mucosa. Furthermore, CD8 T RM cell reactivation was previously shown to significantly upregulate granzyme B production in NK cells. 14 These observations allude to the capacity of T RM -based vaccines to bridge multiple effector components and impart a synergistic effect for the potential control of mucosal HIV infection.
We hypothesized that intravaginal exposure of mice to whole inactivated HIV-1 would initiate in vivo cross-presentation of p24 Gag epitopes, mirroring the reactivation of CD8 T RM cells with exogenous peptides. Non-infectious HIV-1 particles can be acquired and cross-presented by antigen-presenting cells, resulting in the activation of antigen-specific T cells from HIV-infected individuals. 52 However, the tissue-wide activation state was not induced with whole inactivated virus, and we attribute this divergence to several key differences that exist with the peptide-based reactivation model. In contrast to the intravaginal peptide instillation, the maximum practical dose of whole inactivated virus preparations used in our studies contained 17-fold less cognate p24 Gag antigen. This alludes to a likely physiological threshold of cognate antigen concentration required to effectively stimulate CD8 T RM cells. We also speculate that the activation kinetics induced by cross-presentation of whole inactivated virus antigen in antigen-presenting cells would be comparatively delayed due to additional intracellular antigen processing pathways, as opposed to the direct major histocompatibility complex-I binding of exogenous peptides. 67 Lastly, the use nonreplicating viral particles with static antigenic loads would likely be less efficient in stimulating CD8 T RM cells compared with live replication-competent viruses, which would exponentially increase the amount of antigen available. Future nonhuman primate studies utilizing live viral challenge models are more likely to mimic transmission of HIV-1 in humans and the corresponding level of protection conferred by CD8 T RM cells.
In summary, we demonstrate that vaccination strategies using live viral vectors result in the establishment of HIVspecific CD8 T RM cells at the frontline barrier of the vaginal mucosa. The anatomical localization of these cells combined with their ability to rapidly induce recruitment in both innate and adaptive immune arms may provide heightened local surveillance and immunity for the protection against vaginal HIV-1 exposure.
METHODS
Mice immunizations. All animal procedures were approved by the University of Melbourne Animal Ethics Committee. Female BALB/c mice at 6-8 weeks of age were used in all experiments. H1N1 (Flu(PR8)-p24) or H3N2 (Flu(X31)-p24) subtype recombinant influenza viruses expressing the HIV-1 subtype B Gag p24 capsid gene were developed as described previously. 32 Mice were anesthetized by isoflurane inhalation before immunizations. Intranasal immunization was performed with 10 5 p.f.u./50 ml of Flu(PR8)-p24 virus. Five days before intravaginal immunization, mice were injected subcutaneously with 2 mg of medroxyprogesterone acetate (Pharmacia and Upjohn, Pfizer Inc., NY) in 100 ml phosphate-buffered saline (PBS). Mice were intravaginally immunized by atraumatic instillation of Flu(X31)-p24 virus at 10 7 p.f.u./30 ml. For the vector-only control group, matching doses of wild-type PR8 and X31 influenza viruses were used, which were generated as described previously. 32 Lymphocyte isolation and tetramer staining. BALs (3 ml per mouse), whole blood (100 ml per mouse), and vaginal tissues were pooled from three mice per group. Lymphocyte isolation was performed as described previously. 32 Vaginal T cells were enriched using a negative selection EasySep Mouse T Cell Isolation Kit (STEMCELL Technologies, Vancouver, BC, Canada), as per the manufacturer's protocol. Cells were stained with a viability dye (Life Technologies, Thermo Fisher Scientific, Waltham, MA) for 30 min at room temperature and washed once, and Fc blocked with a CD16/32 antibody (93; BioLegend, San Diego, CA) for 10 min at room temperature. Cells were subsequently incubated for 1 h at room temperature with 1.25 mg/ml of phycoerythrin-conjugated major histocompatibility complex-I H2-K D AI9 tetramer or an irrelevant phycoerythrin-conjugated major histocompatibility complex-I H2-K D TUM tetramer (University of Melbourne, Melbourne, VIC, Australia). After tetramer staining, surface staining of cells was performed for 30 min at room temperature using the following surface antibodies: CD3 (17A2; BioLegend), CD4 (GK1.5; BD, Becton, Dickinson and Company, Franklin Lakes, NJ), CD8 (53-6.7; BD), CD103 (2E7; Miltenyi Biotec, Bergisch Gladbach, Germany), CD45 (30-F11; BD), CD44 (IM7; BD), and CD62L (MEL-14; BioLegend). CD4 T-cell CCR5 coreceptor was stained using the CD195 (7A4; eBioscience, Thermo Fisher Scientific) antibody for 30 min at 37 1C. Cells were washed two times with PBS and fixed with Stabilizing Fixative solution (BD). Flow cytometry data were acquired with a BD LSRFortessa (Becton, Dickinson and Company) and analyzed with FlowJo 9.8.3 (Ashland, OR).
Whole tissue IST staining. IST staining was performed as previously described previously. 38 Briefly, vaginal tissues were collected in RF5 media (RPMI1640, 5% fetal calf serum, 10 Immunofluorescence tissue section staining. Seven micrometers of sectioned tissues were fixed in cold acetone solution (Sigma) for 10 min. Tissues were rehydrated with PBS for 10 min and subsequently blocked with 5% (w/v) bovine serum albumin (Sigma) for 1 h. Antibodies were diluted in PBS supplemented with 2% (v/v) normal goat serum (Jackson ImmunoResearch). To amplify the tetramer-PE signal, tissues were stained sequentially with rabbit polyclonal anti-PE antibodies (Novus Biologicals, Littleton, CO) and a secondary goat anti-rabbit immunoglobulin G Alexa Fluor 555 antibody (Life Technologies). Cell staining was performed using the following surface antibodies: CD8 (53.6.7; BioLegend), CD4 (GK1.5 or RM4-5; BioLegend), CD335/NKp46 (29A1.4; BioLegend), CD103 (2E7; BioLegend), CD45R/B220 (RA3-6B2; BioLegend), and Ki67 (11F6; BioLegend). Addressin expression on endothelial vessels was detected using VCAM-1/CD106 (429; BioLegend) and CD31 (MEC13.3; BioLegend) antibodies. Secondary staining of nonconjugated primary antibodies was performed with goat anti-rat immunoglobulin G Alexa . 52 Vaginal canals of anesthetized mice were gently swabbed with calcium alginate swabs (Puritan) moistened with PBS. Twenty microliters of peptide solution or 30 ml of inactivated virus were administered intravaginally by atraumatic instillation.
Statistical analysis. Analyses were performed using Prism 6.0 (GraphPad Software, La Jolla, CA). Data sets were analyzed by a Kruskal-Wallis test, followed by Mann-Whitney tests. A Bonferroni adjustment was used to set a new P value level (0.05 Ä n; where n is the number of comparisons made) for these analyses; P valueso(0.05 Ä n) were considered significant. Correlation P values were determined using a Spearman's test.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/mi
